REGN5093-M114

REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) [1].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; c-Met/HGFR; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

[REGN5093-M114]

References & Citations

[1]Dardare J, et al., REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer? Transl Lung Cancer Res. 2024 Aug 31;13 (8) :2082-2086.